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Abstract. Prolonging the clinical effectiveness of β-lactams, which remain first-line antibiotics 24 
for many infections, is an important part of efforts to address antimicrobial resistance. We 25 
report here that inactivation of the predicted D-cycloserine (DCS) transporter gene cycA re-26 
sensitized MRSA to β-lactam antibiotics. The cycA mutation also resulted in hyper-27 
susceptibility to DCS, an alanine analogue antibiotic that inhibits alanine racemase and D-28 
alanine ligase required for D-alanine incorporation into cell wall peptidoglycan (PG). Alanine 29 
transport was impaired in the cycA mutant and this correlated with increased susceptibility 30 
to oxacillin and DCS. The cycA mutation or exposure to DCS were both associated with the 31 
accumulation of muropeptides with tripeptide stems lacking the terminal D-ala-D-ala and 32 
reduced PG crosslinking, prompting us to investigate synergism between β-lactams and DCS. 33 
DCS re-sensitised MRSA to β-lactams in vitro and significantly enhanced MRSA eradication by 34 
oxacillin in a mouse bacteraemia model. These findings reveal alanine transport as a new 35 
therapeutic target to enhance the susceptibility of MRSA to β-lactam antibiotics. 36 
 37 
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 40 
Introduction 41 
Whilst many bacteria can exhibit resistance to select antimicrobials, isolates of the human 42 
pathogen Staphylococcus aureus can express resistance to all licensed anti-staphylococcal 43 
drugs. This results in significant morbidity and mortality, with up to 20% of patients with 44 
systemic methicillin resistant S. aureus (MRSA) infections dying, despite receiving treatment 45 
with anti-staphylococcal drugs [1]. As part of our efforts to identify improved therapeutic 46 
approaches for MRSA infections, we recently described the novel use of b-lactam antibiotics 47 
to attenuate the virulence of MRSA-induced invasive pneumonia and sepsis [2]. We 48 
demonstrated that oxacillin-induced repression of the Agr quorum-sensing system and 49 
altered cell wall architecture resulted in downregulated toxin production and increased MRSA 50 
killing by phagocytic cells, respectively [2]. Supporting this in vitro data, a randomised 51 
controlled trial involving 60 patients showed that the b-lactam antibiotic flucloxacillin in 52 
combination with vancomycin shortened the duration of MRSA bacteraemia from 3 days to 53 
1.9 days [3, 4].  54 
Because expression of methicillin resistance in S. aureus impacts fitness and virulence and is 55 
a regulated phenotype, further therapeutic interventions may also be possible. The 56 
complexity of the methicillin resistance phenotype is evident among clinical isolates of MRSA, 57 
which express either low-level, heterogeneous (HeR) or homogeneous, high-level methicillin 58 
resistance (HoR) [5-7]. Exposure of HeR isolates to b-lactam antibiotics induces expression of 59 
mecA, which encodes the alternative penicillin binding protein 2a (PBP2a) and can select for 60 
mutations in accessory genes resulting in a HoR phenotype, including mutations that affect 61 
the stringent response and c-di-AMP signalling [8-12]. Because accessory genes can influence 62 
the expression of methicillin resistance in MRSA, targeting the pathways associated with such 63 
genes may identify new ways to increase the susceptibility of MRSA to β-lactams. To pursue 64 
this, we performed a forward genetic screen to identify loci that impact the expression of 65 
resistance to β-lactam antibiotics in MRSA. Using the Nebraska Transposon Mutant Library, 66 
which comprises 1,952 sequence-defined transposon insertion mutants [13], inactivation of 67 
a putative amino acid permease gene, cycA, was found to reduce resistance to cefoxitin, the 68 
β-lactam drug recommended by the Clinical and Laboratory Standards Institute for measuring 69 
mecA-mediated methicillin resistance in MRSA isolates. Amino acid transport and 70 
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susceptibility to oxacillin and D-cycloserine (DCS) were compared in the wild-type and cycA 71 
mutant grown in chemically defined media (CDM), CDM supplemented with glucose (CDMG) 72 
and other complex media. The activity of DCS and b-lactams, alone and in combination, 73 
against MRSA was measured in vitro and in a mouse model of bacteraemia. Peptidoglycan 74 
analysis was performed to compare the impact of the cycA mutation or exposure to DCS on 75 
cell wall structure and crosslinking. Our experiments suggest that therapeutic strategies 76 
targeting alanine transport, which was required for resistance to b-lactams and DCS, and a re-77 
evaluation of DCS may be important as part of efforts to restore the efficacy of b-lactam 78 
antibiotics against MRSA.   79 
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Results 80 
Mutation of cycA increases the susceptibility of MRSA to β-lactam antibiotics and D-81 
cycloserine. To identify new ways of controlling expression of methicillin resistance, we 82 
sought to identify novel mutations involved in this phenotype. An unbiased screen of the 83 
NTML to identify mutants with increased susceptibility to cefoxitin identified NE810 84 
(SAUSA300_1642) (Fig. S1A), which also exhibited a >128-fold increase in susceptibility to 85 
oxacillin (Fig. S1B). NE810 was previously identified among several NTML mutants reported 86 
to be more susceptible to amoxicillin [14], but was not investigated further. Expression of 87 
mecA was not affected in NE810 (Fig. S1C) and genome sequence analysis revealed an intact 88 
SCCmec element and the absence of any other mutations. NE810 was successfully 89 
complemented (Fig. S1B), and transduction of the SAUSA300_1642 allele into several MRSA 90 
strains from a number of clonal complexes and with different SCCmec types was also 91 
accompanied by increased cefoxitin and oxacillin susceptibility (Table 1).  92 
SAUSA300_1642 is annotated as a serine/alanine/glycine transporter with homology to CycA 93 
in Mycobacterium tuberculosis [15, 16], which influences D-cycloserine (DCS) susceptibility in 94 
Mycobacteria [15, 16]. In contrast to the observations in Mycobacteria, our data showed that 95 
NE810 and several unrelated MRSA strains carrying the cycA mutation were significantly more 96 
susceptible to DCS than the wild type JE2 (Fig. S1D, Table 1). The cycA mutation also reduced 97 
the DCS MIC of the MSSA strains 8325-4 and ATCC29213 from 32 to 4 µg/ml. DCS inhibits 98 
alanine racemase (Alr) that converts L-alanine to D-alanine and the Ddl D-alanyl:D-alanine 99 
ligase [17]. A mutant in the putative ddl SAUSA300_2039 gene is not available in the NTML 100 
library, suggesting that it may be essential. However, the alr mutant NE1713 was more 101 
susceptible to cefoxitin (Fig. S2A; MIC=16µg/ml) and DCS (Fig. S2B; MIC <0.25µg/ml), 102 
consistent with an important role for D-alanine in resistance to both antibiotics.  103 
 104 
CycA is required for alanine transport and D-ala-D-ala incorporation into the peptidoglycan 105 
stem peptide. To investigate the role of CycA in amino acid transport, JE2 and NE810 were 106 
grown for 8 h in chemically defined media containing 14mM glucose (CDMG) and amino acid 107 
consumption in spent media was measured. Although no growth rate or yield difference was 108 
noted between JE2 and NE810 in CDMG (Fig. 1A), alanine uptake by NE810 was significantly 109 
impaired compared to JE2 (Fig. 1B). Utilisation of other amino acids by NE810 and JE2, 110 
including serine and glycine, were similar (Fig. S3). Impaired alanine transport in the cycA 111 
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mutant grown in CDMG correlated with increased susceptibility to oxacillin (1 µg/ml) (Fig. 1C) 112 
and DCS (1 µg/ml) (Fig. 1D). These data demonstrate for the first time that CycA in S. aureus 113 
is required for alanine transport. 114 
Quantitative peptidoglycan compositional analysis was performed using UPLC analysis of 115 
muramidase-digested muropeptide fragments extracted from exponential phase cultures of 116 
JE2 and NE810 grown for 220 mins in TSB media (Fig. S4). The PG profile of the cycA mutant 117 
revealed a significant accumulation of tripeptides compared to wild-type JE2 (Fig. 2A,B), 118 
which was associated with a significant reduction in crosslinking (Fig. 2C). In NE810, the dimer, 119 
trimer and tetramer fractions were decreased, which was accompanied by a concomitant 120 
increase in the monomer fraction (Fig. 2D). Consistent with this data, exposure of JE2 to DCS 121 
8µg/ml was also associated with a similar accumulation in muropeptides with tripeptide 122 
stems (Fig. 2B), reduced cross-linking (Fig. 2C), increased muropeptide monomers and 123 
reduced dimers, trimers and tetramers (Fig. 2D). DCS had a strong dose-dependent effect on 124 
the accumulation of muropeptides with tripeptide stems, reduced cross-linking and 125 
accumulation of monomers (Fig. 2A-D). Sub-inhibitory (0.25´ MIC) and 4´ MIC DCS 126 
concentrations, were previously shown to be associated with incorporation of an incomplete 127 
stem peptide (tripeptide) [17] and reduced D-ala-D-ala levels [18], respectively. These data 128 
show that impaired D-ala incorporation in the cycA mutant or following exposure to DCS is 129 
accompanied by reduced PG cross-linking and increased b-lactam susceptibility. 130 
 131 
Mutation of cycA or exposure to D-cycloserine increases the susceptibility of MRSA to b-132 
lactam antibiotics. Previously reported synergy between DCS and β-lactam antibiotics [17, 133 
19] suggests that impaired alanine uptake in the cycA mutant may have the same impact on 134 
cell wall biosynthesis as DCS-mediated inhibition of Alr and Ddl. To further investigate this, 135 
we compared the activity of DCS and β-lactam antibiotics, alone and in combination, against 136 
JE2 and NE810. Checkerboard microdilution assay fractional inhibitory concentration indices 137 
(ΣFICs ≤0.5) revealed synergy between DCS and several licensed b-lactam antibiotics with 138 
different PBP selectivity against JE2 and USA300 FPR3757 (Table 1). Oxacillin and nafcillin 139 
were not included in checkerboard assays because measurement of their MICs involves 140 
supplementing the media with 2% NaCl, which distorts the MIC of DCS (data not shown).  141 
Using the MRSA strains JE2, USA300, DAR173, DAR22, DAR169 and their corresponding cycA 142 
mutants, the kinetics of killing by DCS, oxacillin and cefoxitin, alone and in combination was 143 
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measured over 24h using antibiotic concentrations corresponding to 0.125´, 0.25´ and 0.5´ 144 
MICs. Recovery of growth in media supplemented with oxacillin or cefoxitin alone was evident 145 
after 8 h (Fig. 3), reflecting the selection and expansion of HoR mutants as described 146 
previously [2, 18, 20]. Recovery of growth in cultures exposed to DCS alone was also evident 147 
(Fig. 3), which may correlate with our observation that mutants resistant to DCS (on BHI agar 148 
supplemented with 128 µg/ml DCS) arise at a rate of approximately 5.5 ´ 10-8 per cell per 149 
generation. Using combinations of DCS and oxacillin or cefoxitin at 0.125´ MIC did not achieve 150 
a ³2 log10 reduction in the number of CFU/ml (data not shown). However, at 0.5´ MIC for 151 
strains JE2, USA300, DAR173 and DAR22, DCS (16 µg/ml)/oxacillin (32 µg/ml) and DCS (16 152 
µg/ml)/cefoxitin (32 µg/ml) combinations achieved a ³5 log10 reduction in the number of 153 
CFU/ml compared to oxacillin, cefoxitin or DCS alone (Fig. 3). For strain DAR169, DCS/b-lactam 154 
combinations at 0.25´ MIC was sufficient to achieve a ³5 log10 reduction in CFUs recovered 155 
compared to the individual antibiotics (Fig. 3). DCS/b-lactam combinations at 0.5´ MIC were 156 
also able to achieve ³5 log10 reduction in the number of CFU/ml against the methicillin 157 
resistant S. epidermidis (MRSE) strain RP62A [21] compared to either antibiotic alone (Fig. S5). 158 
Checkerboard experiments with fourteen MRSA strains and MRSE strain RP62A further 159 
revealed synergy (ΣFICs ≤0.5) between DCS and a range of b-lactam antibiotics with different 160 
penicillin binding protein (PBP) specificity, namely cefoxitin (PBP4), cefaclor (PBP3), 161 
cefotaxime (PBP2), piperacillin-tazobactin (PBP3/b-lactamase inhibitor) and imipenem (PBP1) 162 
(Table 1). 163 
This synergy appears to be specific to b-lactams and no synergy (ΣFICs > 0.5) was measured 164 
between DCS and several antibiotics that are used topically or systemically for the 165 
decolonization or treatment of patients colonized/infected with S. aureus or MRSA 166 
(clindamycin, trimethoprim, mupirocin, ciprofloxacin), or several antibiotics to which S. 167 
aureus isolates commonly exhibit resistance (tobramycin, kanamycin and spectinomycin) 168 
(Table S1). Furthermore the cycA mutation had no impact on susceptibility to any of these 169 
non-b-lactam antibiotics (apart from ermB-encoded clindamycin resistance on the 170 
transposon). 171 
 172 
Combination therapy with DCS and oxacillin significantly reduces the bacterial burden in 173 
the kidneys and spleen of mice infected with MRSA. The virulence of the NE810 mutant and 174 
the therapeutic potential of oxacillin in combination with DCS in the treatment of MRSA 175 
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infections were assessed in mice. Treatment with oxacillin or DCS alone significantly reduced 176 
the number of CFUs recovered from the kidneys of mice infected with JE2 (Fig. 4). 177 
Furthermore the oxacillin/DCS combination was significantly more effective than either 178 
antibiotic alone and the combination was equally effective in reducing the bacterial burden 179 
in the kidneys of animals infected with JE2 or NE810 when compared to no treatment 180 
(p≤0.0001) (Fig. 4) demonstrating the capacity of DCS to significantly potentiate the activity 181 
of b-lactam antibiotics against MRSA under in vivo conditions. Unexpectedly, oxacillin- or DCS-182 
mediated eradication of NE810 infections in the kidneys was similar to JE2 (Fig. 4). In the 183 
spleen, only oxacillin/DCS combination treatment was associated with a significant reduction 184 
in the number of CFUs recovered from mice infected with JE2 or NE810 (Fig. S6). 185 
 186 
Alanine transport and resistance to oxacillin and DCS in chemically defined medium are not 187 
dependent on cycA. The failure of oxacillin or DCS treatment to enhance the eradication of 188 
NE810 infections in the mouse bacteraemia model prompted us to further characterise the 189 
growth conditions used for the in vitro antibiotic susceptibility assays. Specifically we 190 
investigated the role of glucose, which we previously reported to increase the growth 191 
requirement for amino acids [22], and which we reasoned may be important for CycA-192 
dependent alanine transport. Growth of JE2 and NE810 was similar in CDM lacking glucose 193 
(Fig. 5A) and uptake of alanine (Fig. 5B) and other amino acids (Fig. S7) was unchanged in 194 
NE810 compared to JE2. Furthermore NE810 and JE2 grew equally well in CDM supplemented 195 
with oxacillin and DSC (Fig. 5C and D). These data explain in part why the cycA mutant does 196 
not exhibit increased b-lactam and DCS susceptibility in the mouse bacteraemia model and 197 
further reveal the strong correlation between alanine transport and susceptibility to oxacillin 198 
and DCS.   199 
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Discussion 200 
The exploitation of antibiotic re-purposing as part of concerted efforts to address the 201 
antimicrobial resistance crisis has been hampered by a lack of mechanistic data to explain 202 
demonstrated therapeutic potential and the perception that studies attempting to identify 203 
new uses for existing drugs are not hypothesis-driven. In this study, we revealed that CycA 204 
was required for full expression of resistance to b-lactam antibiotics and DCS. Loss of function 205 
of this putative alanine transporter significantly increased the susceptibility of MRSA to b-206 
lactam antibiotics, an outcome that could be reproduced through exposure to DCS, which 207 
targets the Alr and Ddl enzymes in the early steps of cell wall biosynthesis. 208 
The potential of b-lactam/DCS combinations for treatment of MRSA infections follows a 209 
recent report that DCS can also potentiate the activity of vancomycin against a laboratory-210 
generated vancomycin highly-resistant S. aureus (VRSA) strain in vitro and in a silkworm 211 
infection model [23]. The excellent safety profile of β-lactam antibiotics makes these drugs 212 
particularly attractive as components of combination antimicrobial therapies. When used in 213 
the treatment of tuberculosis DCS (trade name Seromycin, The Chao Centre) is typically 214 
administered orally in 250 mg tablets twice daily for up to two years. At this dosage, the DCS 215 
concentration in blood serum is generally 25-30 µg/ml, which is similar to the concentrations 216 
used in our in vitro and in vivo experiments. The known neurological side effects associated 217 
with DCS therapy [24, 25] mean that this antibiotic is unlikely to be considered for the 218 
treatment of MRSA infections unless alternative therapeutic approaches have been 219 
exhausted. Oxacillin/DCS combination therapy was significantly more effective than DCS or 220 
oxacillin alone over a 5-day therapeutic window suggesting that further studies on using DCS 221 
to augment b-lactams as a treatment option for recalcitrant staphylococcal infections are 222 
merited. 223 
Mutation of cycA increases the susceptibility of MRSA to b-lactam antibiotics and results in 224 
hyper-susceptibility to D-cycloserine, whereas a cycA point mutation in M. bovis contributes, 225 
in part, to increased DCS resistance presumably by interfering with transport into the cell [16]. 226 
In E. coli, cycA mutations can also result in increased resistance or have no effect on DCS 227 
susceptibility depending on the growth media [26-30], suggesting that CycA is primarily 228 
important for DCS resistance under conditions when its contribution to amino acid transport 229 
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is also important. Our data showing that mutation of cycA was not associated with increased 230 
DCS resistance strongly suggests that CycA has no role in uptake of this antibiotic in S. aureus.  231 
Under growth conditions where CycA is required for alanine transport (in nutrient/glucose-232 
replete media), mutation of cycA or DCS-exposure have similar effects on the structure of S. 233 
aureus peptidoglycan (Fig. 8). Consistent with previous studies in S. aureus [17] and in M. 234 
tuberculosis [31], our studies showed a dose-dependent accumulation of muropeptides with 235 
a tripeptide stem in MRSA exposed to DCS. The cycA mutation was also associated with the 236 
increased accumulation of muropeptides with a tripeptide stem. These data indicate that a 237 
reduced intracellular alanine pool or inhibition of Alr and Ddl is associated with reduced D-238 
ala-D-ala incorporation into the PG stem peptide. The increased accumulation of tripeptides 239 
in turn interferes with normal PBP transpeptidase activity and offers a plausible explanation 240 
for increased susceptibility to b-lactam antibiotics. The importance of the terminal stem 241 
peptide D-ala-D-ala for b-lactam resistance has previously been reported. Mutation of the 242 
murF-encoded ligase, which catalyses of the D-ala-D-ala into the stem peptide also increased 243 
b-lactam (but not DCS) susceptibility [32, 33]. Similarly growth of a HoR MRSA strain in media 244 
supplemented with high concentrations of glycine was accompanied by replacement of the 245 
D-ala-D-ala with D-ala-gly and decreased methicillin resistance [34].  246 
Impaired uptake of alanine in CDMG correlated with increased susceptibility to oxacillin and 247 
DCS, suggesting that alanine utilisation via CycA is important to make D-alanine available for 248 
cell wall biosynthesis and consequently resistance to b-lactams. Consistent with this, NE810 249 
also exhibited increased oxacillin susceptibility in BHI, TSB and MH media. However no change 250 
in alanine transport or susceptibility to oxacillin and DCS was measured in CDM lacking 251 
glucose, which may explain the failure of oxacillin and DCS to more efficiently eradicate NE810 252 
infections in the mouse bacteraemia model. The availability of nutrients such as glucose and 253 
amino acids varies in different niches colonised by S. aureus during infection ranging from 254 
glucose-rich in organs such as the liver [35], to glucose-depleted in established abscesses [36].  255 
In turn this impacts the role of amino acids as carbon sources [22, 37], and potentially the 256 
activity of CycA in alanine transport and b-lactam susceptibility. Furthermore, normal alanine 257 
transport in the cycA mutant grown in CDM indicates that an alternative alanine transport 258 
mechanism(s) may be active under these growth conditions (Fig. 6). Identification of this 259 
alternative alanine permease may be important in the development of therapeutic strategies 260 
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targeting alanine transport to increase b-lactam susceptibility in MRSA, while elucidation of 261 
the role of glucose in the control of alanine transport should provide new insights into b-262 
lactam resistance.  263 
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Materials and Methods 264 
Bacterial strains, growth conditions and antimicrobial susceptibility testing. Bacterial strains 265 
(Table S2) were grown in Luria Bertoni (LB), brain heart infusion (BHI), Mueller Hinton (MH), 266 
nutrient, sheep blood BHI, chemically defined media (CDM) [38] or CDM 14mM glucose 267 
(CDMG) [38]. 268 
Minimum inhibitory concentrations (MICs) were determined in accordance with CLSI 269 
guidelines using plate and broth dilution assays in MH, or MH 2% NaCl for oxacillin and 270 
nafcillin. Oxacillin MICs were also measured using E-tests (Oxoid) on MH 2% NaCl. Quality 271 
control strains ATCC29213 and ATCC25923 were used for oxacillin and cefoxitin MIC assays, 272 
respectively. 273 
Identification of cefoxitin susceptible MRSA mutant NE810. Cefoxitin (30µg) disks (Oxoid)  274 
were used to measure susceptibility of NTML mutants. The zone diameter for JE2 was 18mm 275 
NE1868 (mecA::Emr) was >35mm and NE810 was 22mm. The cycA transposon insertion in 276 
NE810 was verified by PCR using the primers NE810_Fwd and NE810_Rev (Table S3). Phage 277 
80a was used to transduce the NE810 cycA allele into JE2 and other strains. Genome 278 
sequencing was performed by MicrobesNG using the USA300_FPR3757 genome as a 279 
reference. To complement NE810, cycA was amplified from JE2 on a 1608 bp fragment using 280 
primers NE810F1_Fwd and NE810F1_Rev (Table S3) and cloned into pLI50 using the Clontech 281 
In-fusion kit. 282 
mecA transcription analysis. RT-qPCR was performed on a Roche LightCycler with primers 283 
mecA1_Fwd and mecA1_Rev for mecA and gyrB_Fwd and gyrB_Rev for gyrB (internal 284 
standard) (Table S3), as described previously [2]. Data presented are the average of three 285 
experiments with standard errors. 286 
Amino acid transport studies. Amino acid analysis in spent media from cultures grown in 287 
CDM or CDMG was performed as described previously [22]. 288 
Analysis of peptidoglycan composition in NE810 and JE2 treated with D-cycloserine. 289 
Independent quadruplicate 50ml cultures were grown to A600=0.5, dosed with DCS at 0, 8, 20 290 
or 32 µg/ml for 100 mins, then harvested and resuspended in 5ml PBS (Fig. S4) before 291 
peptidoglycan was extracted as described previously [39]. Mass spectrometry was performed 292 
on a Waters XevoG2-XS QTof mass spectrometer. Structural characterization of muropeptides 293 
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was determined based on their MS data and MS/MS fragmentation pattern, matched with PG 294 
composition and structure reported previously [34, 40-42].  295 
Antibiotic synergy analysis using the microdilution checkerboard assay. Antibiotic synergism 296 
was measured using the checkerboard microdilution method in 96-well plates inoculated with 297 
5 × 105 CFU/ml. Growth or no growth was recorded after 24 h at 37°C. The fractional inhibitory 298 
concentration index (ΣFIC) was calculated for each drug combination in triplicate experiments 299 
with an FIC index ≤0.5 considered synergistic.  300 
Kill curve assays. Overnight cultures adjusted to 107 CFU/ml were exposed to 0.125´, 0.25´, 301 
and 0.5´ MIC of oxacillin, cefoxitin and DCS alone or in combination, and the number of 302 
colony forming units (CFU)/ml enumerated at 0, 2, 4, 8 and 24 h. Data is presented at the 303 
antibiotic concentrations where synergy was measured i.e. 0.5´ MIC for JE2, USA300, 304 
DAR173, DAR22, DAR113, BH1CC, and RP62A, and 0.25´ MIC for DAR169. Synergism was 305 
defined as a ≥2 log10 decrease in the number of CFU/ml in cell suspensions exposed to DCS/b-306 
lactam combinations compared to the most effective individual drug after 8 h. !307 
Mouse infection experiments. 6-8 week-old, age matched, outbred CD1 female mice (Charles 308 
River, UK) were used in a non-lethal model of bacteremia. JE2 and NE810 cultures were grown 309 
to A600=0.5 in BHI, washed in PBS, adjusted to 1×108 CFU/ml. Mice were infected 310 
intravenously (via the tail vein) with 5×106 CFU (n = 10 mice per group). The infections were 311 
left untreated (PBS control) or treated with either 75mg oxacillin/Kg/12 hours, 30mg 312 
DCS/Kg/12 hours or a combination of both (first antibiotic dose administered 16 hours post 313 
infection), before being sacrificed after 5 days. Bacteria present in homogenised spleens and 314 
kidneys recovered from the mice were enumerated on blood agar.  315 
Ethics Statement. Mouse experiments were approved by the UK Home Office (License 316 
Number 40/3602) and the University of Liverpool Animal Welfare and Ethics Committee. This 317 
study was carried out in strict accordance with the UK Animals (Scientific Procedures) Act 318 
1986. All efforts were made to minimize suffering.  319 
Statistical analysis. Two-tailed Student’s t-Tests and one-way ANOVA with Kruskal-Wallis test 320 
followed by Dunn’s multiple comparisons test in the GraphPad Prism application (for the 321 
mouse infection experiments) were used to determine statistically significant differences in 322 
assays performed during this study. A p value <0.05 was deemed significant.  323 
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Figure Legends 339 
Figure 1. Mutation of cycA impairs alanine uptake. A. Growth of JE2 and NE810 in chemically 340 
defined media supplemented with glucose (CDMG). Cell density was measured at A600. B. 341 
Alanine consumption by JE2 and NE810 grown aerobically in CDMG. Residual amino acid was 342 
measured in spent media after 2, 4, 6 and 8 h growth. C and D. Growth of JE2 and NE810 343 
cultures for 12 h in CDMG supplemented with 1 µg/ml oxacillin (C) or 1 µg/ml D-cycloserine 344 
(D). Cell density was measured at A600. 345 
Figure 2. Mutation of cycA or D-cycloserine (DCS) treatment impacts peptidoglycan peptide 346 
stem length and reduces cell wall crosslinking. A. Representative UV chromatograms of 347 
peptidoglycan from wild-type JE2, NE810 and JE2 treated with increasing concentrations of 348 
DCS (8, 20 and 32 μg/ml). Muropeptides with tripeptide stems are numbered 1-3. The 349 
Proposed structures of the three muropeptides with tripeptide stems identified in NE810 and 350 
DCS-treated JE2 cells. NAG, N-acetylglucosamine; NAM, N-acetylmuramic acid; L-Ala, L-351 
alanine; D-Gln, D-glutamine; D-Glu, D-glutamic; L-Lys, L-lysine. The theoretical and observed 352 
neutral masses determined by MS are indicated. B. Relative abundance of muropeptides with 353 
tripeptides in the stem. C. Relative crosslinking efficiency. D. Relative proportions of cell wall 354 
muropeptide fractions based on oligomerization. All errors bars represent 95% confidence 355 
interval (n = 4). Significant differences determined using Students t-test are denoted using 356 
asterisks (* p<0.05; ** p<0.01; *** p<0.001). 357 
Figure 3. In vitro kill curves for D-cycloserine (DCS), oxacillin and cefoxitin with JE2, USA300 358 
FPR3757, DAR173, DAR22, DAR169 and their isogenic cycA mutants. Antibiotics at the 359 
concentrations indicated (µg/ml) were added to suspensions of overnight bacterial cultures 360 
adjusted to 107 CFU/ml in BHI (A600=0.05), incubated at 37oC and the number of CFU/ml 361 
enumerated at 0, 2, 4, 8 and 24 h. The data presented are the mean of three independent 362 
experiments, and standard error of the mean is shown. Antibiotic synergism was defined as a 363 
≥2 log10 decrease in the number of CFU/ml in cell suspensions exposed to DCS/b-lactam 364 
combinations compared to the most effective individual antibiotic alone. 365 
Figure 4. Combination therapy with D-cycloserine and oxacillin significantly reduces the 366 
bacterial burden in the kidneys of mice infected with MRSA. The number of colony-forming 367 
units (CFU) recovered from the kidneys of mice infected by tail vein injection with 5 × 106 JE2  368 
or NE810 (CycA) and left untreated or treated with 75mg of oxacillin (Ox)/kg, 30mg of DCS/kg 369 
or a combination of both Ox and DCS delivered subcutaneously every 12 hours for 5 days. The 370 
first antibiotic dose was given 16 hours after infection. Significant differences determined 371 
using one-way ANOVA with Kruskal-Wallis test followed by Dunn’s multiple comparisons 372 
test are denoted using asterisks (*p≤0.05, **p≤0.01, ****p≤0.0001). The limit of detection 373 
(50 colonies) is indicated with a hashed red line. 374 
Figure 5. Alanine transport and resistance to oxacillin and D-cycloserine in chemically 375 
defined medium are cycA-independent. A. Growth of JE2 and NE810 in chemically defined 376 
medium lacking glucose (CDM). Cell density was measured at A600. B. Alanine consumption by 377 
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JE2 and NE810 grown aerobically in CDM. Residual amino acid was measured in spent media 378 
after 2, 4, 6 and 8 h growth. C and D. Growth (cell density at A600) of JE2 and NE810 cultures 379 
for 12 h in CDM supplemented with 1 µg/ml oxacillin (C) or 1 µg/ml DCS (D).  380 
Figure 6. Proposed model depicting how impaired alanine transport associated with mutation 381 
of CycA or exposure to DCS can inhibit the D-alanine pathway for peptidoglycan biosynthesis 382 
leading to increased susceptibility to b-lactam antibiotics.  383 
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Table 1. Antibacterial activity (minimum inhibitory concentrations, MIC) and drug synergy (fractional inhibitory concentration indices, ΣFIC) of D-cycloserine 
(DCS) and several b-lactam antibiotics with different PBP specificity, namely oxacillin (OX; PBP1, 2, 3), nafcillin (NAF; PBP1), cefoxitin (FOX; PBP4), cefaclor 
(CEC; PBP3), cefotaxime (CTX; PBP2), piperacillin-tazobactin (TZP; PBP3/b-lactamase inhibitor) and imipenem (IMP; PBP1), alone and in b-lactam 




* MIC values for each antibiotic when measured individually; µg/ml 
** MIC values for each antibiotic when measured in combination, also known as the fractional inhibitory concentration (FIC); µg/ml 
*** FIC indices (ΣFIC) for antibiotic combinations. ΣFIC = FIC A + FIC B, where FIC A is the MIC of DCS in combination with the b-lactam/MIC of DCS alone, and FIC B is the 
MIC of the b-lactam in combination with DCS/MIC of the b-lactam alone. Combinations are synergistic when the ΣFIC is ≤0.5 and indifferent when the ΣFIC is >0.5 to <2.  
‡ND. Not determined if strain is susceptible (or hyper-resistant) to b-lactam antibiotic or for cycA mutants with reduced DCS & b-lactam MICs. 
 
Antibiotic ® 














(ΣFIC)*** ¯ Strain 
JE2 64 32 32 64 8/8 (0.37) 64 8/2 (0.28) 64 8/4 (0.31) 32 8/0.5 (0.26) 1 ND 
NE810 (cycA) 0.25 0.5 2 8 ND 4 ND 8 ND 2 ND 0.125 ND 
USA300  64 32 32 64 8/8 (0.37) 64 8/8 (0.37) 64 8/8 (0.37) 64 8/2 (0.28) 1 ND 
USA300 cycA 0.25 1 2 8 ND 4 ND 8 ND 4 ND 0.125 ND 
DAR173 128 128 32 256 4/32 (0.25) 128 8/4 (0.28) 512 8/4 (0.25) 128 4/4 (0.15) 64 4/2 (0.15) 
DAR173 cycA 0.5 8 4 32 ND 16 ND 16 ND 4 ND 1 ND 
DAR22 128 128 32 128 8/8 (0.31) 128 8/8 (0.31) 512 8/4 (0.25) 128 4/4 (0.15) 128 4/1 (0.13) 
DAR22 cycA 0.5 8 0.5 16 ND 16 ND 16 ND 4 ND 0.5 ND 
DAR169 32 32 32 32 8/2 (0.31) 128 4/32 (0.37) 64 4/8 (0.25) 8 4/1 (0.25) 2 ND 
DAR169 cycA 16 4 0.5 16 ND 64 ND 16 ND 2 ND 0.5 ND 
COL 512 256 64 512 8/128 (0.37) 128 16/32 (0.5) >2048 ND 128 32/0.5 (0.5) 256 8/64 (0.37) 
DAR113 128 64 32 128 8/8 (0.3) 64 8/4 (0.3) 256 8/8 (0.2) 128 8/4 (0.2) 16 8/0.5 (0.2) 
BH1CC 256 512 32 256 8/32 (0.3) 128 8/8 (0.3) 1028 8/16 (0.2) 256 8/4 (0.2) 64 8/1 (0.2) 
BH14B(04) 128 64 16 128 4/32 (0.5) 128 4/32 (0.5) 512 4/32 (0.31) 64 4/1 (0.26) 64 2/8 (0.25) 
BH8(03) 128 128 32 128 8/32 (0.5) 256 8/64 (0.5) 128 8/16 (0.25) 128 8/8 (0.3) 64 8/0.5 (0.1) 
BH6 128 128 32 128 8/16 (0.37) 256 8/64 (0.5) 512 8/32 (0.31) 128 8/4 (0.28) 32 8/0.5 (0.26) 
DAR202 64 64 32 128 4/32 (0.37) 128 4/32 (0.37) 64 8/16 (0.5) 64 8/2 (0.28) 4 8/1 (0.5) 
DAR45 2 0.5 32 4 ND 32 8/2 (0.31) 4 ND 2 ND 0.5 ND 
DAR13 128 32 32 128 4/32 (0.37) 128 8/4 (0.28) 128 4/32 (0.37) 32 8/1 (0.28) 8 4/2 (0.37) 
RP62A 128 2 32 64 6/16 (0.5) 64 6/16 (0.5) 32 8/8 (0.5) 8 8/2 (0.5) 32 8/1 (0.2) 
 20 
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1 0 1 0
J E 2
J E 2  D C S  1 6
J E 2  O X A  3 2
J E 2  D C S  1 6  +  O X A  3 2
J E 2  F O X  3 2
J E 2  D C S  1 6  +  F O X  3 2
N E 8 1 0
N E 8 1 0  D C S  1 6
N E 8 1 0  O X A  3 2
N E 8 1 0  F O X  3 2






















1 0 1 0
U S A 3 0 0
U S A 3 0 0  D C S  1 6
U S A 3 0 0  O X A  3 2
U S A 3 0 0  D C S  1 6  +  O X A  3 2
U S A 3 0 0  F O X  3 2
U S A 3 0 0  D C S  1 6  +  F O X  3 2
U S A 3 0 0 c y c A
U S A 3 0 0 c y c A D C S  1 6
U S A 3 0 0 c y c A O X A  3 2
U S A 3 0 0 c y c A  F O X  3 2






















1 0 1 0
D A R 1 7 3
D A R 1 7 3  D C S  1 6
D A R 1 7 3  O X A  6 4
D A R 1 7 3  D C S 1 6  +  O X A  6 4
D A R 1 7 3  F O X  1 2 8
D A R 1 7 3  D C S  1 6  +  F O X  1 2 8
D A R 1 7 3 c y c A
D A R 1 7 3 c y c A D C S  1 6
D A R 1 7 3 c y c A O X A  6 4
D A R 1 7 3 c y c A  F O X  1 2 8






















1 0 1 0
D A R 2 2
D A R 2 2  D C S  1 6
D A R 2 2  O X A  6 4
D A R 2 2  D C S  1 6  +  O X A  6 4
D A R 2 2  F O X  6 4
D A R 2 2  D C S  1 6  +  F O X  6 4
D A R 2 2 c y c A
D A R 2 2 c y c A D C S  1 6
D A R 2 2 c y c A O X A  6 4
D A R 2 2 c y c A F O X  6 4
JE2; SCCmec type IV; CC8 
USA300; SCCmec type IV; CC8
DAR173; SCCmec type IV; CC5 
DAR22; SCCmec type III; CC5 
DAR169; SCCmec type I; CC8 






















1 0 1 0
D A R 1 6 9
D A R 1 6 9  D C S  8
D A R 1 6 9  O X A  8
D A R 1 6 9  D C S  8  +  O X A  8
D A R 1 6 9  F O X  8
D A R 1 6 9  D C S  8  +  F O X  8
D A R 1 6 9 c y c A
D A R 1 6 9 c y c A D C S  8
D A R 1 6 9 c y c A O X A  8











































































































































Impaired alanine transport or exposure to D-cycloserine increases the susceptibility of 
MRSA to b-lactam antibiotics! 
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Table S1. Antibacterial activity (minimum inhibitory concentrations, MIC) and drug synergy (fractional inhibitory concentration indices, ΣFIC) of 
D-cycloserine (DCS), and clindamycin (CLI), tobramycin (TOB), trimethoprim (TMP), mupirocin (MUP), ciprofloxacin (CIP), kanamycin (KAN) and 
spectinomycin (SPT) alone and in DCS/antibiotic combinations, against fourteen S. aureus strains and S. epidermidis RP62A. 
 
 * MIC values for each antibiotic when measured individually; µg/ml 
** MIC values for each antibiotic when measured in combination, also known as the fractional inhibitory concentration (FIC); µg/ml 
*** FIC indices (ΣFIC) for the antibiotic combination. ΣFIC = FIC A + FIC B, where FIC A is the MIC of DCS in combination with the antibiotic/MIC 
of DCS alone, and FIC B is the MIC of the antibiotic in combination with DCS/MIC of the antibiotic alone. The combination is considered 
synergistic when the ΣFIC is ≤0.5, indifferent when the ΣFIC is >0.5 to <2.  






















(ΣFIC) ¯ Strain 
JE2 32 0.25 ND 1 ND 1 ND 32 16/16 (1) 2 ND 64 16/32 (1) 0.25 ND 
USA300  32 2048 32/2048 (2) 0.5 ND 1 ND 32 16/16 (1) 2 ND 64 16/32 (1) 2048 32/2048 (2) 
DAR173 32 0.5 ND 512 32/512 (2) 0.5 ND 256 16/128 (1) 512 16/256 (1) 64 16/32 (1) 0.5 ND 
DAR22 32 0.5 ND 512 16/256 (1) 0.5 ND 256 16/128 (1) 256 16/128 (1) 64 16/32 (1) 0.5 ND 
DAR169 32 0.5 ND 0.5 ND 0.5 4/8 (0.25) 1 ND 2 ND 64 16/32 (1) 0.5 ND 
COL 64 0.5 ND 0.5 ND 0.5 ND 1 ND 0.5 ND 64 16/32 (1) 0.5 ND 
DAR113 32 0.25 ND 0.5 ND 1 ND 0.5 ND 2 ND 64 16/32 (1) 0.25 ND 
BH1CC 32 1024 32/1024 (2) 32 32/32 (2) 256 32/256 (2) 32 16/16 (1) >1024 ND >1024 ND 32 16/8 (0.75) 
BH14B(04) 16 0.5 ND 0.5 ND 0.5 ND 128 16/128 (1.5) 2 ND 64 8/32 (1) 0.5 ND 
BH8(03) 32 1024 32/1024 (2) 0.5 ND 0.5 ND 256 16/128 (1) 8 32/4 (2) 128 16/64 (1) 4 32/4 (2) 
BH6 32 0.5 ND 0.5 ND 0.5 ND >512 16/256 (1) 1 ND 128 16/64 (1) 0.5 ND 
DAR202 32 0.5 ND 128 16/64 (1) 0.5 ND 2 ND  >1024  ND >1024 ND 0.5 ND 
DAR45 32 1024 32/1024 (2) 512 16/256 (1) 0.5 ND 128 16/64 (1) 128 16/64 (1) 512 32/1024 (2) 0.5 ND 
DAR13 32 0.5 ND 0.5 ND 32 16/16 (1) 32 16/16 (1) 2048 ND >1024 ND 0.5 ND 




Table S2. Bacterial strains and plasmids used in this study 
Strains/plasmids Relevant Details   
RN4220 Restriction-deficient laboratory S. aureus 
USA300 FPR3757 Community associated MRSA isolate of the USA300 lineage [43]. SCCmec type IV. CC8. 
JE2 USA300 cured of p01 & p03. Parent of Nebraska Transposon Mutant Library (NTML).  
NE810 
USA300 cycA 
JE2 NTML cycA (SAUSA300_1642) mutation.  Ermr.  
USA300 FPR3757 cycA. Constructed by transduction of cycA::Tn allele from NE810.  
NE1868 JE2 NTML mecA mutation. 
NE1713 JE2 NTML alr (SAUSA300_2027) mutation.  
BH1CC MRSA clinical isolate; SCCmec type II; CC8 [44] 
COL MRSA reference strain; SCCmec type I; CC8 [45]  
BH14(04) MRSA clinical isolate; SCCmec type IV; CC22 [44] 
BH8(03) MRSA clinical isolate; SCCmec type IV; CC22 [44] 
BH6(03) MRSA clinical isolate; SCCmec type II; CC8 [44] 
DAR113 MRSA reference isolate; SCCmec type IV; CC22 [44, 46] 
DAR13 MRSA reference isolate; SCCmec type IV; CC8 [44, 46] 
DAR45 MRSA reference isolate; SCCmec type II; CC30 [44, 46] 
DAR202 MRSA reference isolate; SCCmec type III; CC239 [44, 46] 
DAR173 MRSA reference isolate; SCCmec type IV; CC5 [44, 46]  
DAR173 cycA DAR173 cycA mutant (cycA::Tn allele from NE810) 
DAR22 MRSA reference isolate; SCCmec type III; CC5 [44, 46] 
DAR22 cycA DAR22 cycA mutant (cycA::Tn allele from NE810) 
DAR169 MRSA Reference strain; SCCmec type I; CC8 [44, 46] 
DAR169 cycA DAR169 cycA mutant (cycA::Tn allele from NE810) 
8325-4 NCTC 8325 derivative cured of prophages [47], methicillin susceptible, CC8. 
8325-4 cycA 8325-4 cycA mutant (cycA::Tn allele from NE810). 
ATCC 29213 Methicillin susceptible S. aureus strain for antibiotic susceptibility testing.  
ATCC 29213 cycA ATCC 29213 cycA mutant (cycA::Tn allele from NE810). 
ATCC 25923 Methicillin susceptible S. aureus strain for antibiotic susceptibility testing. 
S. epidermidis RP62A ATCC 35984. Methicillin resistant, biofilm positive. [21] 
E. coli E. coli HST08 
Plasmids 
 
pLI50 E. coli-Staphylococcus shuttle vector. Apr (E. coli), Cmr. (Staphylococcus) 
pcycA pLI50 carrying cycA from JE2 
 
 
Table S3. Oligonucleotide primers used in this study 
Target Gene Primer Name Primer Sequence (5’-3’) 
cycA NE810_Fwd ACAGAATAGCCACAAATAGCACC  
NE810_Rev ACAGAATAGCCACAAATAGCACC 
cycA NE810F1_Fwd GTCTTCAAGAATTCGGCCACAAATAGCACCATTAA 
 NE810F1_Rev CGACTCTAGAGGATCATGTCCCAAGCCCTAAAAC 
mecA mecA1_Fwd TGCTCAATATAAAATTAAAACAAACTACGGTAAC  
mecA1_Rev GAATAATGACGCTATGATCCCAA 
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Figure S1. Mutation of cycA increases the susceptibility of MRSA to b-lactam antibiotics and D-cycloserine. A. 
Chromosomal location of cycA and neighbouring genes icd (isocitrate dehydrogenase), gltA (citrate synthase), pyk 
(pyruvate kinase) and pfkA (6-phosphofructokinase). The locations of transposon insertions in NE810, NE491, 
NE594 and NE1497 mutants from the Nebraska library are indicated. B. E-test measurement of oxacillin minimum 
inhibitory concentrations (MICs) in JE2 (wild type), NE810 (cycA::Tn), NE810 carrying pLI50 (control) and pcycA. C. 
Comparison of relative mecA gene expression by LightCycler RT-PCR in JE2 and NE810 grown to A600=3 in BHI 
media. The data are the average of three independent experiments and standard deviations are shown D. 
Comparison of zones of inhibition around D-cycloserine 30µg disks on lawns of JE2, NE810 (cycA::Tn), NE810 pLI50 
(control) and NE810 pcycA grown on Mueller Hinton (MH) agar.  
.CC-BY 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.










Figure S2. A. Susceptibility of JE2 (wild type), NE1868 (mecA::Tn), NE810 (cycA::Tn), and 
NE1713 (alr::Tn) grown on MH agar to cefoxitin (FOX, 30µg disks). B. Susceptibility of JE2 
(wild type) and NE1713 (alr::Tn) grown on MH agar to D-cycloserine (DCS, 30µg disks).  
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Figure S3. Amino acid consumption by JE2 and NE810 grown aerobically in chemically defined media containing 14mM 
of glucose (CDMG). Residual amino acids were measured in spent media after 2, 4, 6 and 8 h growth. 
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Figure S4. Preparation of cell suspensions for peptidoglycan extraction and structural analysis by UPLC-MS. 50 ml flask 
cultures were inoculated into fresh BHI media from overnight cultures at a starting cell density of A600=0.05 and incubated 
at 37oC. The number of CFU/ml was enumerated every 1-2 h for 6 h and again after 24 hours. For JE2 cultures being dosed 
with DCS, the antibiotic was added after approximated 2 h (A600≈0.5) and the cells collected after a further 100 mins. Cells 
from untreated JE2 and NE810 control cultures were collected at the same time point. 
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Figure S5. In vitro kill curves for D-cycloserine (DCS), oxacillin and cefoxitin with methicillin resistant S. epidermidis strain RP62A. 
Antibiotics at the concentrations indicated (equivalent to 0.5´MIC) were added to suspensions of overnight bacterial cultures 
adjusted to 107CFU/ml in BHI, incubated at 37oC and the number of CFU/ml enumerated at 0, 2, 4, 8  and 24 h. The data presented 
are the mean of three independent experiments. Antibiotic synergism was defined as a ≥2 log10 decrease in the number of CFU/ml 
in cell suspensions exposed to DCS/b-lactam combinations compared to the most effective individual antibiotic alone.
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Figure S6. Combination therapy with D-cycloserine and oxacillin significantly reduces the bacterial burden in the 
spleen of mice infected with MRSA. The number of colony-forming units (CFU) recovered from the spleens of mice 
infected by tail vein injection with 5 × 106 JE2  or NE810 (CycA) and left untreated or treated with 75mg of oxacillin 
(Ox)/kg, 30mg of DCS/kg or a combination of both Ox and DCS delivered subcutaneously every 12 hours for 5 days. 
The first antibiotic dose was given 16 hours after infection. Significant differences determined using one-way 
ANOVA with Kruskal-Wallis test followed by Dunn’s multiple comparisons test are denoted using asterisks 
(*p≤0.05). The limit of detection (50 colonies) is indicated with a hashed red line.  
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Figure S7. Amino acid consumption by JE2 and NE810 grown aerobically in chemically defined media lacking glucose (CDM). 
Residual amino acids were measured in spent media after 2, 4, 6 and 8 h growth. 
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